Portage Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Portage Biotech prognostiziert ein Gewinnwachstum at 77.8% per annum. Der Gewinn pro Aktie wird voraussichtlich wachsen um 89.7% pro Jahr.

Wichtige Informationen

81.0%

Wachstumsrate der Gewinne

104.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.8%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	11 Mar 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Portage Biotech GAAP EPS of -$0.13

Aug 29

Portage Biotech rises after getting full ownership of its anti-cancer agonist platform

Jul 20

Portage Biotech acquires Tarus Therapeutics, a developer of adenosine receptor antagonists

Jul 06

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:PRTG - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2026	N/A	-18	N/A	N/A	1
3/31/2025	N/A	-16	N/A	N/A	1
6/30/2024	N/A	-71	-13	-13	N/A
3/31/2024	N/A	-75	-14	-14	N/A
12/31/2023	N/A	-145	-16	-16	N/A
9/30/2023	N/A	-113	-15	-15	N/A
6/30/2023	N/A	-109	-13	-13	N/A
3/31/2023	N/A	-105	-12	-12	N/A
12/31/2022	N/A	-17	-10	-10	N/A
9/30/2022	N/A	-14	-9	-9	N/A
6/30/2022	N/A	-16	-7	-7	N/A
3/31/2022	N/A	-17	-7	-7	N/A
12/31/2021	N/A	-21	-5	-5	N/A
9/30/2021	N/A	-19	-5	-5	N/A
6/30/2021	N/A	-18	-5	-5	N/A
3/31/2021	N/A	-16	-4	-4	N/A
12/31/2020	N/A	-6	-4	-4	N/A
9/30/2020	N/A	-6	-4	-4	N/A
6/30/2020	N/A	-5	-3	-3	N/A
3/31/2020	N/A	-5	-4	-4	N/A
12/31/2019	N/A	-6	-3	-3	N/A
9/30/2019	N/A	-5	-3	-3	N/A
6/30/2019	N/A	-4	-2	-2	N/A
3/31/2019	N/A	-3	-1	-1	N/A
12/31/2018	N/A	124	-1	-1	N/A
9/30/2018	N/A	124	-1	-1	N/A
6/30/2018	N/A	124	-1	-1	N/A
3/31/2018	N/A	124	N/A	-1	N/A
12/31/2017	N/A	-10	N/A	2	N/A
9/30/2017	N/A	-16	N/A	2	N/A
6/30/2017	N/A	19	N/A	2	N/A
3/31/2017	N/A	16	N/A	-1	N/A
12/31/2016	N/A	24	N/A	-6	N/A
9/30/2016	N/A	27	N/A	-7	N/A
6/30/2016	N/A	-8	N/A	-8	N/A
3/31/2016	N/A	-6	N/A	-6	N/A
12/31/2015	N/A	-6	N/A	-6	N/A
9/30/2015	N/A	-3	N/A	-5	N/A
6/30/2015	N/A	-3	N/A	-3	N/A
3/31/2015	N/A	-3	N/A	-3	N/A
12/31/2014	N/A	-4	N/A	-3	N/A
9/30/2014	N/A	-3	N/A	-3	N/A
6/30/2014	N/A	-3	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PRTG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: PRTG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: PRTG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von PRTG schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: PRTG wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von PRTG in 3 Jahren voraussichtlich hoch sein wird

Portage Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 16% to US$16.00

Recent updates

Portage Biotech Inc. announced delayed 20-F filing

Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives

New major risk - Financial position

New major risk - Market cap size

Portage Biotech Inc. Presents Updates on its iNKT and Adenosine Programs at the Society for Immunotherapy of Cancer's 38th Annual Meeting

New major risk - Revenue and earnings growth

New major risk - Share price stability

Price target decreased by 16% to US$16.00

Portage Biotech Inc. Announces First Patient Dosed in Phase 1A Trial of Portage-6 in Select Solid Tumors

Portage Biotech Reports Updated Interim Data for Lead Inkt Engager, Port-2, in A Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer At the 2023 American Society for Clinical Oncology (Asco) Annual Meeting

Portage Biotech Inc. Presents Updated Data on the Phase 1/2 Trial Evaluating Port-2 At the Society for Immunotherapy of Cancer’S (Sitc) 37Th Annual Meeting

Portage Biotech Inc., Annual General Meeting, Nov 10, 2022

Portage Biotech Inc. Provides Research and Development Update

Portage Biotech GAAP EPS of -$0.13

Portage Biotech Inc. Announces Leadership Updates

Portage Biotech rises after getting full ownership of its anti-cancer agonist platform

Portage Biotech Inc. (NasdaqCM:PRTG) signed an agreement to acquire Tarus Therapeutics, Inc. for $53.3 million.

Portage Biotech Inc. (NasdaqCM:PRTG) signed an agreement to acquire Tarus Therapeutics, Inc.

Portage Biotech acquires Tarus Therapeutics, a developer of adenosine receptor antagonists

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

Portage Biotech Inc. Provides an Update on Its Clinical Development Programs and Announces Its Development Goals for the Remainder of 2022

Portage Biotech Announces Executive Changes

Portage Biotech Inc. Highlights First Patient Dosed in Imp-Mel Study of Port-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (Nsclc)

Portage Biotech Inc. has completed a Follow-on Equity Offering in the amount of $23 million.

Portage Biotech Inc. Highlights Safety and Survival Data from Intensity Therapeutics' It-01 Study of Int230-6 (Port-1) At Asco 2021 Annual Meeting

Juvenescence Ltd. acquired Portage pharmaceuticals Ltd from Portage Biotech Inc. (NasdaqCM:PRTG).

Portage Biotech's Common Shares Deleted from Other OTC

Portage Biotech Inc. announced that it has received $6.98145 million in funding

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken